Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study - Cheng, Ying; Wang, Qiming; Li, Kai; Shi, Jianhua; Liu, Ying; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Lou, Donghua; Yu, Hao; et al. (British journal of cancer, 2021)
Keywords: 692/4028/67/1612/2143; 692/4028/67/2328; Administration, Oral; Adult; Aged; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy; China; Clinical trials; Double-Blind Method; Double-blind studies; Drug Administration Schedule; Drug Resistance; Epidemiology; Female; Humans; Indoles - administration & dosage; Indoles - adverse effects; Lung cancer; Lung Neoplasms - drug therapy; Male; Middle Aged; Molecular Medicine; Oncology; Patients; Placebos; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Quinolines - administration & dosage; Quinolines - adverse effects; Small cell lung carcinoma; Small Cell Lung Carcinoma - drug therapy; Survival Analysis; Treatment Outcome; Young Adult; China